Back to search

France· FR:61404477

LANTUS 100 unités/ ml, solution injectable en cartouche

A medicinal product containing insuline glargine, registered in France by SANOFI AVENTIS (ALLEMAGNE), on the national reimbursement list.

Reimbursed in France (Assurance maladie)

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedLANTUS 100 unités/ ml, solution injec…ATC—REGISTER NO.FR:61404477PACKS LISTED1CHECKEDSeptember 12, 2026

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
INSULINE GLARGINE
Manufacturer
SANOFI AVENTIS (ALLEMAGNE)
Country
France (FR)
ATC code
—
Reimbursed
Yes
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • cip13
    3400935463203
    5 cartouche(s) en verre de 3 ml
    EUR 36.43

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Insuline glargine in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All insuline glargine products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Abasaglar, Abasaglar Kwikpen
  • Liechtenstein · Abasaglar, Abasaglar Kwikpen
  • Norway · Lantus, Lantus Solostar

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ca1a8ccd-7d45-4a65-a94b-84e8471b57be
GET /v1/drugs/ca1a8ccd-7d45-4a65-a94b-84e8471b57be?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "61404477",
  "date_amm": "2000-06-09",
  "type_amm": "Procédure centralisée",
  "numero_ue": "EU/1/00/134",
  "substance": "INSULINE GLARGINE",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "solution injectable",
  "voies_administration": "sous-cutanée",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Non"
}

See everything about insuline glargine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.